RenovoRx, Inc.

NasdaqCM RNXT

RenovoRx, Inc. Market Capitalization on January 14, 2025: USD 31.68 M

RenovoRx, Inc. Market Capitalization is USD 31.68 M on January 14, 2025, a 103.93% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

RenovoRx, Inc. 52-week high Market Capitalization is USD 36.66 M on December 09, 2024, which is 15.72% above the current Market Capitalization.
RenovoRx, Inc. 52-week low Market Capitalization is USD 14.67 M on January 24, 2024, which is -53.69% below the current Market Capitalization.
RenovoRx, Inc. average Market Capitalization for the last 52 weeks is USD 25.92 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: RNXT

RenovoRx, Inc.

CEO	Mr. Shaun R. Bagai
IPO Date	Aug. 26, 2021
Location	United States
Headquarters	4546 El Camino Real
Employees	8
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Key trends

Past 5 years